Cited by 408Diabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes

The DOI matches its Crossref record.

Sulfonylureas in NIDDM

Groop, Leif C·1992·Diabetes Care

Open this paper in CoChat — free account

Abstract

Sulfonylureas have represented the backbone of oral therapy in non-insulin-dependent diabetes mellitus for > 30 yr. Despite this, our knowledge about the mode of actions of these agents is limited, and the use of them is far from rational. Sulfonylureas lower blood glucose concentrations primarily by stimulating insulin secretion. The evidence for clinically significant extrapancreatic effects is scanty. Therefore, the effect of sulfonylurea is limited to patients with preserved β-cell function, with the best effect observed in the early stages of the disease. Sulfonylurea treatment is often started relatively late and is continued when the agents can no longer achieve the treatment goals. Drug dosages are increased to maximum recommended doses, although there is no evidence for a dose-response relationship between the sulfonylurea dose and its biological effect. To rationalize the use of sulfonylureas, we should ask the questions to whom, how much, and for how long? The decision to stop treatment is as important as the decision to start treatment.

Integrity signals

Registry

Crossref · 10.2337/diacare.15.6.737

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 404

Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients
Schotborgh, C. E. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00036-9 · Cited by 52
Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus
Kerényi, Z., Samer, H., James, R., Yan, Y., & Stewart, M. W. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.09.009 · Cited by 52
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Tacelli, M., Celsa, C., Magro, B., Giannetti, A., Pennisi, G., Spatola, F., & Petta, S. (2018) · Pharmaceuticals · doi:10.3390/ph11040121 · Cited by 53
Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca 2+ regulation prevail over changes in insulin content
Anello, M., Gilon, P., & Henquin, J. C. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702731 · Cited by 52
Insulin resistance and diabetes mellitus
DeFronzo, R. A., & Prato, S. D. (1996) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(96)00046-3 · Cited by 50
A novel drug delivery system for type 1 diabetes: Insulin-mimetic vanadyl-poly(γ-glutamic acid) complex
Karmaker, S., Saha, T., Yoshikawa, Y., et al. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.05.005 · Cited by 49
Cardiovascular effects of sulphonylurea derivatives
Smits, P. (1997) · Diabetologia · doi:10.1007/s001250051438 · Cited by 49
Sulfonylurea Pharmacotherapy Regimen Adherence in a Medicaid Population: Influence of Age, Gender, and Race
Sclar, D. A., Robison, L. M., Skaer, T. L., Dickson, W. M., Kozma, C. M., & Reeder, C. E. (1999) · The Science of Diabetes Self-Management and Care · doi:10.1177/014572179902500406 · Cited by 49
Stevioside does not cause increased basal insulin secretion or β-cell desensitization as does the sulphonylurea, glibenclamide: Studies in vitro
Chen, J., Jeppesen, P. B., Abudula, R., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.08.012 · Cited by 48
Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel‐Champ. with Glyburide in Alloxan Induced Diabetic Mice
Badole, S. L., Patel, N. M., Thakurdesai, P. A., & Bodhankar, S. L. (2007) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nem010 · Cited by 48
Rationale, Design, and Methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Magee, M. F., & Isley, W. L. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.024 · Cited by 47
Pharmacological Management of Diabetes
Emilien, G., Maloteaux, J., & Ponchon, M. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00034-5 · Cited by 47
Synthesis and glycosidase inhibitory activity of aminocyclitols with a C6- or a C7-ring
Gravier‐Pelletier, C., Maton, W. M., Dintinger, T., Tellier, C., & Merrer, Y. L. (2003) · Tetrahedron · doi:10.1016/j.tet.2003.09.049 · Cited by 46
Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
Mendez, C. E., & Umpierrez, G. E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.3.180 · Cited by 48
Evaluation of the effectiveness of an ambulatory teaching/treatment programme for non-insulin dependent (type 2) diabetic patients
Domenech, M. I., Assad, D., Mazzei, M. E., Kronsbein, P., & Gagliardino, J. J. (1995) · Acta Diabetologica · doi:10.1007/bf00838482 · Cited by 46
Association Between Glycosylated Hemoglobin and Intentional Weight Loss in Overweight and Obese Patients With Type 2 Diabetes Mellitus
Shantha, G. P. S., Kumar, A. A., Kahan, S. I., & Cheskin, L. J. (2012) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721712443293 · Cited by 47
Antihyperglycaemic Agents Drug Interactions of Clinical Importance
Scheen, A. J., & Lefèbvre, P. J. (1995) · Drug Safety · doi:10.2165/00002018-199512010-00003 · Cited by 45
Recycling a Borate Complex for Synthesis of Polycarbonate Polyols: Towards an Environmentally Friendly and Cost‐Effective Process
Patil, N. G., Bhoopathi, S., Chidara, V. K., Hadjichristidis, N., Gnanou, Y., & Feng, X. (2020) · ChemSusChem · doi:10.1002/cssc.202001395 · Cited by 43
Prevention of Complications in Non-Insulin-Dependent Diabetes Mellitus (NIDDM)
Wolffenbuttel, B. H. R., & van Haeften, T. W. (1995) · Drugs · doi:10.2165/00003495-199550020-00006 · Cited by 42
Reduction of the acute bioavailability of metformin by the α‐glucosidase inhibitor acarbose in normal man
SCHEEN, A. J., FERREIRA ALVES de MAGALHAES, A. C., SALVATORE, T., & LEFEBVRE, P. J. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02257.x · Cited by 42
Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients
Shukla, U., Chi, E. M., & Lehr, K. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c397 · Cited by 42
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Spectrum · doi:10.2337/diaspect.22.1.6 · Cited by 40
Synthesis and Antidiabetic Activity of 3,6,7‐Trisubstituted‐2‐(1H‐imidazol‐2‐ylsulfanyl)quinoxalines and Quinoxalin‐2‐yl isothioureas
Bahekar, R. H., Jain, M. R., Gupta, A. A., Goel, A., Jadav, P., Patel, D. N., Prajapati, V. M., & Patel, P. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200700024 · Cited by 40
Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly
Mooradian, A. D. (1996) · Drugs · doi:10.2165/00003495-199651060-00002 · Cited by 40
Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors
Ovais, S., Pushpalatha, H., Reddy, G. B., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.046 · Cited by 38
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
Scheen, A. J. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100002 · Cited by 43
Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer program - the ‘PKC syndrome’
McCarty, M. F. (1996) · Medical Hypotheses · doi:10.1016/s0306-9877(96)90243-1 · Cited by 37
Combination of the insulin sensitizer, pioglitazone, and the long‐acting GLP‐1 human analog, liraglutide, exerts potent synergistic glucose‐lowering efficacy in severely diabetic ZDF rats
Larsen, P. J., Wulff, E. M., Gotfredsen, C. F., Brand, C. L., Sturis, J., Vrang, N., Knudsen, L. B., & Lykkegaard, K. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00865.x · Cited by 36
Computational and Pharmacological Evaluation of Carveol for Antidiabetic Potential
Ahmed, M. S., Khan, A., Kury, L. T. A., & Shah, F. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00919 · Cited by 38
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients
Fischer, S., Patzak, A. R., Rietzsch, H., Schwanebeck, U., Köhler, C. U., Wildbrett, J., Fuecker, K., Temelkova-Kurktschiev, T. S., & Hanefeld, M. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00239.x · Cited by 36
RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
Zhe, R., Li, L., Fei, F., et al. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-32 · Cited by 35
Retracted
Effects of Aspirin and Ibuprofen on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Subjects
Kubacka, R. T., Antal, E. J., Juhl, R. P., et al. (1996) · Annals of Pharmacotherapy · doi:10.1177/106002809603000103 · Cited by 34
Killer Proteases and Little Strokes—How the Things that do not Kill You Make You Stronger
O’Duffy, A. E., Bordelon, Y. M., & McLaughlin, B. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600380 · Cited by 32
Management of periodontal disease in patients with diabetes- good clinical practice guidelines: A joint statement by Indian Society of Periodontology and Research Society for the Study of Diabetes in India
Jain, A. R., Chawla, M. S., Kumar, A., Chawla, R., Grover, V., Ghosh, S. K., Pandit, N., & CHAWLA, P. M. (2020) · Journal of Indian Society of Periodontology · doi:10.4103/jisp.jisp_688_20 · Cited by 38
The impact of pharmacotherapy on weight management in type 2 diabetes
Hauner, H. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800956 · Cited by 33
Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone
Buysschaert, M., Bobbioni, E., Starkie, M., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00029.x · Cited by 32
Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic β-cells
Mukai, E., Ishida, H., Kato, S., Tsuura, Y., Fujimoto, S., Ishida‐Takahashi, A., Horie, M., Tsuda, K., & Seino, Y. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.1.e38 · Cited by 32
The Effect of the Timing and the Administration of Acarbose on Postprandial Hyperglycaemia
Rosak, C., Nitzsche, G., König, P., et al. (1995) · Diabetic Medicine · doi:10.1111/j.1464-5491.1995.tb00409.x · Cited by 31
Cardiovascular effects of sulphonylurea derivatives
Smits, P., Bijlstra, P. J., Rüssel, F. G. M., Lutterman, J. A., & Thien, T. A. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(96)01230-2 · Cited by 31
Gliclazide modified release: From once-daily administration to 24-hour blood glucose control
Harrower, A. (2000) · Metabolism · doi:10.1053/meta.2000.17823 · Cited by 30
Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure
Costa, B., & Piñol, C. (1997) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(97)00083-1 · Cited by 30
Pharmacotherapy of Diabetes: New Developments
Mogensen, C. E. (2007) · Springer eBooks · doi:10.1007/978-0-387-69737-6 · Cited by 30
Pharmacotherapy of Type 2 Diabetes Mellitus
Rendell, M., & Kirchain, W. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19171 · Cited by 30
New treatments for patients with type 2 diabetes mellitus
Wolffenbuttel, B. H. R., & Graal, M. B. (1996) · Postgraduate Medical Journal · doi:10.1136/pgmj.72.853.657 · Cited by 30
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: Study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release
Bouider, N., Fhayli, W., Ghandour, Z., Boyer, M., Harrouche, K., Florence, X., Pirotte, B., Lebrun, P., Faury, G., & Khelili, S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.043 · Cited by 29
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients
Abbink, E. J., Pickkers, P., Rosendaal, A. J. V., Lutterman, J. A., Tack, C. J., Rüssel, F. G. M., & Smits, P. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00663.x · Cited by 29
The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs
van Leeuwen, N., Swen, J. J., Guchelaar, H., & Hart, L. M. ‘. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0076-3 · Cited by 31
INSULIN GLARGINE (LANTUS®)
Owens, & Griffiths, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11297.x · Cited by 38
Quality of medical products for diabetes management: a systematic review
Saraswati, K., Sichanh, C., Newton, P. N., et al. (2019) · BMJ Global Health · doi:10.1136/bmjgh-2019-001636 · Cited by 28
Hypoglycaemic effect of Croton cuneatus in streptozotocin-induced diabetic rats
Torrico, F., Cepeda, M., Guerrero, G., Melendez, F., Blanco, Z., Canelón, D. J., Díaz, B., Compagnone, R. S., & Suarez, A. I. (2007) · Revista Brasileira de Farmacognosia · doi:10.1590/s0102-695x2007000200005 · Cited by 28
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
Yaribeygi, H., Simental‐Mendía, L. E., Barreto, G. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28420 · Cited by 27
Issues Surrounding Tight Glycemic Control in People with Type 2 Diabetes Mellitus
Cerveny, J. D., Leder, R. D., & Weart, C. W. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17375 · Cited by 27
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.1.4 · Cited by 29
Synthesis, Characterization, Antioxidant Activity, and DNA-Binding Studies of 1-Cyclohexyl-3-tosylurea and Its Nd(III), Eu(III) Complexes
Xi, P.-X., Xu, Z.-H., Liu, X., et al. (2008) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.56.541 · Cited by 27
Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome
Codario, R. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-441-8 · Cited by 28
Exposure to glibenclamide increases rat beta cells sensitivity to glucose
Patanè, G., Piro, S., Anello, M., et al. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703131 · Cited by 27
Effect of gliclazide treatment on insulin secretion and β-cell mass in non-insulin dependent diabetic Goto–Kakisaki rats
Dachicourt, N., Bailbé, D., Gangnerau, M.-N., Serradas, P., Ravel, D., & Portha, B. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00718-3 · Cited by 27
Stevioside counteracts the glyburide-induced desensitization of the pancreatic beta-cell function in mice: studies in vitro
Chen, J., Jeppesen, P. B., Nordentoft, I., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.08.009 · Cited by 26
Amelioration of Hyperglycemia and Metabolic Syndromes in Type 2 Diabetic KKAy Mice by Poly(γ‐glutamic acid)oxovanadium(IV) Complex
Karmaker, S., Saha, T., Yoshikawa, Y., & Sakurai, H. (2007) · ChemMedChem · doi:10.1002/cmdc.200700132 · Cited by 24
Can correction of sub-optimal coenzyme Q status improve beta-cell function in type II diabetics?
McCarty, M. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0681 · Cited by 35
Glibenclamide induces apoptosis by activating reactive oxygen species dependent JNK pathway in hepatocellular carcinoma cells
Yan, B., Peng, Z., Xing, X., et al. (2017) · Bioscience Reports · doi:10.1042/bsr20170685 · Cited by 25
Effect of Sulphonylurea Therapy on Plasma Insulin, Intact and 32/33 Split Proinsulin in Subjects with Type 2 Diabetes Mellitus
Davies, M. J., Metcalfe, J., Day, J., Grenfell, A., Hales, C. N., & Gray, I. P. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00274.x · Cited by 25
A Zinc(II)/Poly(γ‐glutamic acid) Complex as an Oral Therapeutic for the Treatment of Type‐2 Diabetic KKAy Mice
Karmaker, S., Saha, T., Yoshikawa, Y., et al. (2008) · Macromolecular Bioscience · doi:10.1002/mabi.200800190 · Cited by 24
The Effects of Glibenclamide, a KATP Channel Blocker, on the Warm‐Up Phenomenon
Ferreira, B. M. A., Moffa, P. J., Falcão, A. M. G. M., Uchida, A. H., Camargo, P., Pereyra, P., Soares, P. R., Hueb, W. A., & Ramires, J. A. F. (2005) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2005.00650.x · Cited by 22
Combination Therapy For Type 2 Diabetes
Mudaliar, S. R., & Henry, R. R. (1999) · Endocrine Practice · doi:10.4158/ep.5.4.208 · Cited by 24
The morphological and biochemical effects of glibornuride on rat liver in experimental diabetes
Bolkent, S., Yanardağ, R., Bulan, Ö. K., & Saçan, Ö. (2004) · Human & Experimental Toxicology · doi:10.1191/0960327104ht444oa · Cited by 24
Potentiation of Sulfonylurea Action by an EPAC-selective cAMP Analog in INS-1 Cells: Comparison of Tolbutamide and Gliclazide and a Potential Role for EPAC Activation of a 2-APB-sensitive Ca2+ Influx
Jarrard, R. E., Wang, Y., Salyer, A. E., Pratt, E. P. S., Soderling, I. M., Guerra, M. L., Lange, A. M., Broderick, H. J., & Hockerman, G. H. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081943 · Cited by 22
Natural compounds with DPP‐4 inhibitory effects: Implications for the treatment of diabetes
Yaribeygi, H., Atkin, S. L., & Sahebkar, A. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28467 · Cited by 23
Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells
Bokvist, K. B., Høy, M., Buschard, K., Holst, J. J., Thomsen, M. K., & Gromada, J. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00754-2 · Cited by 24
A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes
Johnson, M. L., Krosnick, A., Carson, P., McDade, A. M., & Laraway, K. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80132-x · Cited by 23
Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes
Ewan, R. P. (2009) · Frontiers in bioscience · doi:10.2741/3532 · Cited by 21
The effect of glibenclamide on insulin secretion at normal glucose concentrations
Riefflin, A., Ayyagari, U., Manley, S. E., Holman, R. R., & Lévy, J. (2014) · Diabetologia · doi:10.1007/s00125-014-3399-1 · Cited by 22
Oral Antihyperglycaemics
Jennings, P. E. (1997) · Drugs & Aging · doi:10.2165/00002512-199710050-00001 · Cited by 22
JTT‐608 restores impaired early insulin secretion in diabetic Goto‐Kakizaki rats
Ohta, T., Furukawa, N., Komuro, G., Yonemori, F., & Wakitani, K. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702481 · Cited by 20
Possible hypoglycemic action of SX-fraction targeting insulin signal transduction pathway
Konno, S., Alexander, Zade, & Choudhury (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s41891 · Cited by 21
Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide
Banerjee, A., Verma, P. R. P., & Gore, S. P. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0246-0 · Cited by 23
Capitalizing on Prescribing Pattern Variation to Compare Medications for Type 2 Diabetes
Prentice, J. C., Conlin, P. R., Gellad, W. F., et al. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.2674 · Cited by 21
Effects of Tolbutamide on Vascular ATP-Sensitive Potassium Channels in Humans
Bijlstra, P. J., Rüssel, F. G. M., Thien, T. A., et al. (1996) · Hormone and Metabolic Research · doi:10.1055/s-2007-979843 · Cited by 21
Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione
Kautzky‐Willer, A., Tura, A., Winzer, C., Wagner, O. F., Ludvik, B. H., Hanusch‐Enserer, U., Prager, R., & Pacini, G. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00568.x · Cited by 21
Drug Administration in Patients with Diabetes Mellitus
Gilbert, R. E., Cooper, M. E., & Krum, H. (1998) · Drug Safety · doi:10.2165/00002018-199818060-00005 · Cited by 19
Oxovanadium(IV)–Porphyrin Complex as a Potent Insulin-Mimetic. Treatment of Experimental Type 1 Diabetic Mice by the Complex [meso-Tetrakis(4-sulfonatophenyl)porphyrinato]oxovanadate(IV)(4−)
Saha, T., Yoshikawa, Y., Yasui, H., & Sakurai, H. (2006) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.79.1191 · Cited by 20
Pharmacokinetics, Pharmacodynamics, and Dose-Response Relationship of Repaglinide in Type 2 Diabetes
Strange, P., Schwartz, S. L., Graf, R. J., Polvino, W. J., Weston, I. E., Marbury, T. C., Huang, W., & Goldberg, R. B. (1999) · Diabetes Technology & Therapeutics · doi:10.1089/152091599317143 · Cited by 19
Exploiting complementary therapeutic strategies for the treatment of type II diabetes and prevention of its complications
McCarty, M. F. (1997) · Medical Hypotheses · doi:10.1016/s0306-9877(97)90219-x · Cited by 20
Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists
El‐Zahabi, M. A., Bamanie, F. H., Ghareeb, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179605 · Cited by 19
Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
Nogueira, C., Souto, S. B., Vinha, E., Braga, D. C., & Carvalho, D. M. (2013) · HORMONES · doi:10.14310/horm.2002.1436 · Cited by 19
Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations
Gregorio, F., Ambrosi, F., Cristallini, S., Filipponi, P., & Santeusanio, F. (1996) · Acta Diabetologica · doi:10.1007/bf00571936 · Cited by 19
Novel Substituted Aminoalkylguanidines as Potential Antihyperglycemic and Food Intake-Reducing Agents
Tassoni, E., Giannessi, F., Brunetti, T., Pessotto, P., Renzulli, M. L., Travagli, M., Rajamäki, S., Prati, S., Dottori, S., Corelli, F., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001636 · Cited by 19
Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects
Ampudia‐Blasco, F. J., Heinemann, L., Bender, R., Schmidt, A., Heise, T., Berger, M., & Starke, A. A. R. (1994) · Diabetologia · doi:10.1007/bf00417695 · Cited by 19
A Comparison of Agents Used to Manage Type 2 Diabetes Mellitus
Bell, D. S. H. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403020-00001 · Cited by 19
Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart
Legtenberg, R. J., Houston, R. J. F., Oeseburg, B., et al. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00974-8 · Cited by 19
JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats
Ohta, T., Furukawa, N., Yonemori, F., & Wakitani, K. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00952-2 · Cited by 17
Treatment of Non-Insulin-Dependent Diabetes Mellitus and its Complications
Ilarde, A., & Tuck, M. L. (1994) · Drugs & Aging · doi:10.2165/00002512-199404060-00004 · Cited by 20
New insights concerning the molecular basis for defective glucoregulation in soluble adenylyl cyclase knockout mice
Holz, G. G., Leech, C. A., & Chepurny, O. G. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.023 · Cited by 18
Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes
Garber, A. J. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00054.x · Cited by 19
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients
Guvener, N. D., & Gedik, O. (1999) · Acta Diabetologica · doi:10.1007/s005920050151 · Cited by 18
Pharmacologic Treatment Options for Non-Insulin-Dependent Diabetes Mellitus
Tan, G. H., & NELSON, R. L. (1996) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64841-6 · Cited by 18
Complementary measures for promoting insulin sensitivity in skeletal muscle
McCarty, M. F. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90065-2 · Cited by 19
Section Review—Oncologic, Endocrine & Metabolic: Potential Use of Vanadium Compounds in the Treatment of Diabetes Mellitus
Srivastava, A. K. (1995) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.4.6.525 · Cited by 18
The Economics of Pharmacotherapy for Diabetes Mellitus
Costa, B., Arroyo, J., & Sabaté, A. (1997) · PharmacoEconomics · doi:10.2165/00019053-199711020-00004 · Cited by 18
Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca2+-dependent exocytosis in pancreatic α- and β-cells
Høy, M., Olsen, H. L., Andersen, H. S., Bokvist, K. B., Buschard, K., Hansen, J. B., Jacobsen, P., Petersen, J. S., Rorsman, P., & Gromada, J. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01537-1 · Cited by 18

Authors: Groop, L. C.
Affiliations: Helsinki University Hospital (FI)
Corresponding author: Groop, Leif C
ORCID: Groop, Leif C
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 1992-06-01
Volume: 15
Issue: 6
Pages: 737-754
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/diacare.15.6.737
OpenAlex: W1989058656
Cited by: 408
References: 0
Citations by year: 2026: 1 · 2025: 3 · 2024: 2 · 2022: 4 · 2021: 1 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 21 · 2013: 12 · 2012: 16
FWCI: 11.01
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
Keywords: sulfonylureas, type 2 diabetes, oral antidiabetic therapy, insulin secretion, beta-cell function, drug dosing, treatment duration, treatment discontinuation
MeSH terms: Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Islets of Langerhans, Sulfonylurea Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sulfonylureas in NIDDM

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks